The purpose of the study was to evaluate the influence of establishing a protocol for the use of combined sodium benzoate and sodium phenylacetate (SBSP) (Ammonul®) to treat acute hyperammonemia. This was a retrospective, single-center study in a 24-bed medical and surgical pediatric intensive care unit (PICU) in a tertiary care teaching maternal-child hospital in Canada. Inclusion criteria were age <18 years, PICU admission between 1 January 2000 and 30 June 2016, and SBSP treatment. An SBSP delivery protocol was implemented in our hospital on 30 August 2008 in order to improve management of acute hyperammonemia. Patients were assigned to one of the two groups, without or with protocol, depending on date of admission. SBSP was ordered 34 times during the study period, and 23 orders were considered for analysis (14 with and 9 without protocol). Patient characteristics were similar between groups. The median time from diagnosis to prescription was significantly shorter in the protocol group [40 min (21-82) vs 100 min (70-150), p = 0.03)] but the median time from diagnosis to administration of the treatment was equivalent [144 min (90-220) vs 195 (143-274), (p = 0.2)]. Other clinical outcomes did not differ. This study is the first to compare two SBSP delivery strategies in the treatment of acute hyperammonemia in this PICU setting. Implementation of a delivery protocol shortened the time from diagnosis of hyperammonemia to prescription of SBSP and helped us identify other parameters that can be improved to optimize treatment delivery.
Introduction
Ammonia is a waste product of cellular amino acid catabolism. In the liver, ammonia is converted to urea via the urea cycle and in the central nervous system to glutamine by the astrocytic enzyme, glutamine synthetase (Braissant et al. 2013; Barsotti 2001; Cagnon and Braissant 2007; Haberle et al. 2012) . These metabolic pathways normally maintain ammonia at low serum concentrations. Prolonged hyperammonemia can lead to damage of several organs (Smith et al. 2005; Ducharme-Crevier et al. 2015; Dasarathy et al. 2017) , some of which are potentially irreversible (Cagnon and Braissant 2007; Enns 2008) or lethal (Enns et al. 2007; Unsinn et al. 2016 ). Hyperammonemia's deleterious effects are not brain specific, but neurologic symptoms are often its first clinical expression (Braissant et al. 2013; Cagnon and Braissant 2007; Dasarathy et al. 2017; Butterworth 2002; Butterworth 2014 ). In the acute phase, hyperammonemia can lead to brainstem swelling with cerebral edema and intracranial hypertension (Braissant et al. 2013; Cagnon and Braissant 2007; Braissant 2010; Cooper and Plum 1987; Feillet and Leonard 1998) . This is independent of the underlying cause of the hyperammonemia. In inherited disorders of metabolism, hyperammonemia is an independent risk factor for mortality and poor neurologic outcome. The risk of brain injury is directly associated with ammonia serum level and length of time >180 μmol/l (Enns et al. 2007; Bachmann 2003; McBryde et al. 2006; Ozanne et al. 2012; Uchino et al. 1998) . This is consistent with the adult literature, which shows an association between ammonia serum level and the risk of intracranial hypertension (Bernal et al. 2007; Clemmesen et al. 1999; Davern 2007) . In pediatrics, hyperammonemia is most commonly due to inborn errors of metabolism, especially urea cycle disorders, but it can also be caused by either primary or secondary liver disease (DucharmeCrevier et al. 2015; Gunduz et al. 2015; Kamate et al. 2010) . In addition to restriction of protein intake, management of hyperammonemia includes administration of ammonia scavengers and more invasive removal therapies (Haberle et al. 2012; Enns et al. 2007 ). The initial treatment of acute hyperammonemia due to inborn errors of metabolism is based on stopping protein intake, minimizing endogenous protein breakdown by providing sufficient energy from carbohydrates, and administration of sodium phenylbutyrate, sodium phenylacetate, and/or sodium benzoate (SB). These ammonia scavenger compounds reduce ammonia production by conjugating with amino acids, forming nitrogen-rich byproducts that are eliminated in urine independently of the urea cycle. Renal replacement therapy for ammonia removal purposes is considered in acute life-threatening situations (Haberle et al. 2012; Enns et al. 2007) . Some mild episodes of hyperammonemia can be controlled with SB alone, whereas in more severe episodes, intravenous administration of combined SB and sodium phenylacetate (SBSP) (Ammonul® (Ucyclyd Pharma) should provide a faster decrease of ammonia level. Phenylacetate allows elimination of double the quantity of nitrogen through formation of phenylacetylglutamine, whereas SB uses the glycine pathway. SBSP requires an individual patient-named weight-based order, which involves multiple dose calculations and the need for a central venous catheter (Haberle et al. 2012; Enns et al. 2007; Husson et al. 2016) . In order to standardize the management of acute hyperammonemia in the pediatric intensive care unit (PICU) and to facilitate the use of ammonia scavengers via IV in a safe and efficient fashion, a specific hyperammonemia protocol including SBSP administration was implemented and its clinical impact assessed retrospectively using a beforeand-after study design.
Materials and methods

Settings and design
We conducted a single-center retrospective study in the 24-bed pediatric medical, surgical, and cardiac intensive care unit of a tertiary-care maternal-child teaching hospital (SainteJustine University Hospital, Montreal, Canada). The study was approved by Sainte-Justine Hospital Institutional Review Board (number 2017-1365), including a waiver for obtaining individual consent due to the retrospective nature of the study and the universally applied standardized intervention.
Population
All patients admitted to Sainte-Justine Hospital for whom SBSP was prescribed between 1 January 2000 and 30 June 2016 were eligible. Inclusion criteria were as follows: child <18 years of age, admitted to the PICU with confirmed hyperammonemia diagnosis (defined as two plasma ammonia levels >80 μmol/l in children <1 year of age and >55 μmol/l in older children) (Maranda et al. 2007) , and administration of SBSP IV. Exclusion criteria were as follows: SBSP ordered or started in another hospital, preventive administration of SBSP without hyperammonemia, and brain death or decision to withdraw or withhold treatment at hospital admission. In the situation of repeated PICU admissions for a single patient, each hyperammonemia episode was considered as independent.
Study protocol
Retrospective identification of patients was done by crossreferencing the pharmacy database with the laboratory and PICU databases. Patients were included if they received SBSP treatment. Those with hyperammonemia episodes were allocated to one of the two groups depending on whether SBSP was prescribed before or after 30 August 2008, when the delivery protocol was implemented (Annex 1). Patients with episodes documented before that date formed the control group, and those with episodes after that date formed the protocol group. The delivery protocol aimed to facilitate and secure ammonia scavenger prescription, providing information on dosing, administration modalities, and other associated care, such as optimal blood drawing techniques for ammonemia measurement, fluid administration, and caloric intake (Annex 1). The decision to treat with SBSP was made with the attending physician. SBSP was administered only through a central IV line. Apart from using the protocol, there was no other identifiable difference between the two periods: patient management followed institutional practice for monitoring, hemodynamic and respiratory support, sedation and analgesia, and other treatment decisions. Similarly, patient discharge to other wards conformed to institutional practice in both groups, i.e., the presence of neurological, respiratory, and hemodynamic stability without need for supportive measures.
Outcomes
The primary outcome was the interval between diagnosis of hyperammonemia and prescription of ammonia scavenger treatment. Time of diagnosis was defined as the moment when SBSP treatment was indicated, i.e., either hyperammonemia according to hyperammonemia treatment guidelines (Haberle et al. 2012) or neurologic or digestive symptoms compatible with hyperammonemia in a previously known patient with a potentially causative underlying condition at admission or during hospital stay. Time of administration was considered as the time when the infusion was started. Secondary outcomes included time from diagnosis to administration and from prescription to administration, as well as time to ammonemia <200 μmol/l, time to normal ammonia plasma level, length of PICU stay, length of ventilatory support, use of renal replacement therapy, and death in the PICU or during hospital stay.
Data sources and studied variables
Data were extracted from medical charts and collected with a standardized form after codification. Collected data included sex, age, weight, underlying condition, etiology of hyperammonemia, biological characteristics at inclusion, severity scores for death and organ dysfunction [Pediatric Index of Mortality (PIM2), (Slater et al. 2003) and Pediatric Logistic Organ Dysfunction (PELOD) (Leteurtre et al. 2003) ], other hyperammonemia treatments (medication and/or extracorporal removal therapies and/or liver transplant), ventilatory support, and outcomes. Serum ammonia levels were noted at the time of admission in the PICU, time of inclusion (treatment administration), and at 4, 8, 12, 24, 36, 48, 60, 72, 84 , 96 h after treatment initiation (when data was available).
Data analysis and statistics
According to distribution (Shapiro-Wilk test), continuous variables were expressed as median (1st and 3rd quartiles) and categorical variables as number (percentage). Comparisons between groups were made using MannWhitney U test for continuous variables and Fisher's exact test or chi-square test for categorical variables, as appropriate. Time to events (from diagnosis to SBSP prescription, from diagnosis to SBSP administration, from SBSP prescription to its administration, to discharge from PICU and to plasma ammonia levels <200 μmol/l and < 100 μmol/l) were evaluated with Kaplan-Meier curves, and a log-rank test was performed. A p value of 0.05 was considered statistically significant. Statistical analyses were performed using open access R software (version 3.3.1, http://cran.r-project.org/).
Results
SBSP was ordered 34 times (for 24 different patients) during the study period; five were not included in the analysis because they did not fulfill the inclusion/exclusion criteria: one patient >18 years, two orders were never administered due to a quick decrease of ammonia level on the second blood sample, and two patients were not admitted to the PICU. Of the remaining 29 prescriptions, 11 were written before 30 August 2008 and 18 after: six of these were excluded (3 prescriptions started in another hospital, 2 patients withheld therapy decisions, and one was a pre-livertransplant preventive prescription). The remaining 23 episodes (18 patients) were allocated to either the control or the protocol group as depicted on the flowchart (Fig. 1) . Of the 23 episodes, 15 patients had a single episode, two patients had two, and one patient had four. Demographic data and characteristics on admission were similar between groups (Table 1) .
Parameters related to SBSP order and administration characteristics are shown in Table 2 . The time from diagnosis to SBSP prescription was significantly shorter in the protocol group. Median time from diagnosis to SBSP administration was lower in the protocol group, but this did not reach statistical significance (Table 2, Fig. 2) . The median duration of SBSP treatment was 3 days per episode [2-4], with no significant difference between groups [2 (2-4) vs 4 (3-6), p = 0.1]. Associated treatments are detailed in Table 2 .
Clinical outcome data are presented in Table 3 . The median time to the first plasma ammonia value <200 µm/ l was lower in the protocol group, but this difference was not statistically significant (Fig. 3) . There was a nonsignificant lower use of renal replacement therapy in the protocol group. Implementation of the protocol did not significantly influence the lengths of PICU and hospital stays or the clinical outcomes studied. 
Discussion
Our study showed that the implementation of a standardized hyperammonemia treatment protocol reduced the time from diagnosis of hyperammonemia to prescription of ammonia scavengers. This was associated with a trend toward a faster decrease of plasma ammonia to <200 μmol/l. However, this study did not show an influence of this protocol on clinical outcomes. SBSP is a combination of two ammonia scavengers administered IV for treatment of hyperammonemia, most commonly due to urea cycle disorders (Haberle et al. 2012; Enns et al. 2007; Alfadhel et al. 2016) . The efficiency and safety of SBSP in children were previously established (Enns et al. 2007 ). However, acute hyperammonemia is a relatively rare diagnosis, and SBSP use remains sporadic. Prescribing SBSP requires challenging calculations and dilutions, and SBSP must be administered rapidly in the setting of acute hyperammonemia. Delivery protocols can facilitate the prescription process and reduce the risk of error (Haberle et al. 2012 ). This study is the first to compare two SBSP delivery strategies in pediatrics. The main objective was to evaluate the influence of an institutional SBSP delivery protocol on the time from diagnosis of hyperammonemia to the prescription of SBSP. A retrospective before-and-after implementation study design seemed appropriate to assess the influence of the protocol.
The protocol efficiently reduced the time to SBSP prescription but did not significantly decrease the time to SBSP administration. We estimated an acceptable delay from prescription to administration to be 60 min (n = 9), which relates to the time needed by the pharmacy for Reason for excessive delay between prescription and administration, n (%) Admission in PICU delay prescipion validation, preparation of the infusion, and for safety controls. We examined delays that were >60 min (n = 14). Most of these delays were due to the time needed to secure a central IV line for administration of SBSP (n = 8, 57%). SBSP is hyperosmolar and requires a central line for safe administration, particularly in infants and neonates (Haberle et al. 2012; Husson et al. 2016; Matoori and Leroux 2015) . Since rapid treatment of hyperammonemia could improve patient outcome by decreasing time spent >180 μmol/l (Enns et al. 2007; Bachmann 2003; McBryde et al. 2006; Ozanne et al. 2012; Uchino et al. 1998) , an alternative to SBSP while waiting for central IV access could be a transient SB infusion alone. In a retrospective analysis conducted between 2000 and 2010 in six French pediatric reference centers for metabolic diseases, Husson et al. (2016) assessed the safety and efficiency of peripheral IV administration of SB alone. The authors report 95 administration episodes in 61 patients aged 0-35 years (median 3 years). In that series, treatment resulted in a blood ammonium level ≤ 100 μmol/l in 92.8% of episodes. Mortality was 13% (8/61), and 18 minor complications related to infusion were reported (infusion diffusion, edema, local inflammatory lesion). Our study complements that of Husson et al. report that SBSP was used in ten episodes, including six that were considered as failures of treatment with SB alone. In our study, the relatively greater patient severity is reflected by the overall patient mortality rate of The results of our study are limited by its single-center and retrospective design, which could have influenced data collection and participated in an ascertainment bias. Our study is also limited by the fact that we analyzed hyperammonemia treatment episodes and not individual patients in each group. Over the inclusion period, a single patient was treated several times. His being older at each visit made the protocol group seem older than the control group, especially considering our small sample sizes. Differences appeared regarding other clinical characteristics between groups, with a tendency toward a sicker state in the control group regarding extracorporal removal therapy, severity score at admission (not statistically significant), and ammonemia maximal value (p = 0.05). The number of treatment episodes was insufficient for sensitive measurement of the protocol's impact on clinical outcomes. Furthermore, we included all episodes of acute hyperammonemia regardless of the underlying cause. Indeed, liver-failure-associated hyperammonemia's initial therapeutic management relies on reducing digestive ammonia production and absorption (Wijdicks 2016) and not on SBSP. Despite the generally accepted use of SB in this setting (Sushma 1992) , SBSP remains controversial in patients with liver failure because of the risk of phenylacetate accumulation and potential intoxication, as the conjugation of phenylacetate with glutamine in hepatocytes could be impaired in liver failure (Jacques et al. 2016) . It is possible that SBSP could have been initiated prior to having documented liver damage in these specific patients, as SBSP is not routinely used in this population at our facility. Phenylacetate intoxication was not assessed in our study.
Conclusion
This study showed that implementing an SBSP prescription and delivery protocol reduces the time from diagnosis of hyperammonemia to prescription of SBSP. This is an important advantage in conditions like acute hyperammonemia, which arises uncommonly and unpredictably in the PICU. The study also reveals other key parameters that influence time to administration and could be addressed to attain optimal patient outcome. Future prospective studies could shed light on what parameters could be optimized to further improve clinical endpoints in this specific population of critically ill children. 
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